The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Meiji's Japan sales performance.
Japanese regulator clears the drug for first-line use in NSCLC. AstraZeneca’s blockbuster-in-waiting lung cancer treatment Tagrisso has just been approved in Japan as a first-line treatment ... Dave Fredrickson, Executive Vice President, Head of the
The agency now has 14 offices, five of which are based in the UK, six are in the US, and a further three in Serbia, Australia and Japan.
Astellas acquires UK gene therapy company Quethera. Japan’s Astellas Pharma is to acquire UK-based gene therapy company Quethera for $85m. ... The drug is already approved in other major markets, including Europe, Japan, Australia and Canada.
Kyowa Kirin has been selling Poteligeo in Japan since 2012, and the company says its approval in the US is a key milestone on the path to becoming a global specialty ... Sales of Poteligeo in Japan were 1.9bn yen ($17m) in fiscal 2017, and are
Overall sales fell 5% to $10.33bn, however, thanks to generic competition taking another chunk out of cholesterol drug Crestor (rosuvastatin) sales, particularly in Europe and Japan. ... its launch in Japan, while Tagrisso grew 82% to $760m on the back
[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]
Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...